Longitudinal CSF isoprostane and MRI atrophy in the progression to AD

Very little data exist to evaluate the value of longitudinal CSF biological markers for Alzheimer's disease (AD).Most studies indicate that tau and amyloid beta markers do not reflect disease progression. We now report on a longitudinal, three-time point, CSF Isoprostane (IsoP) and quantitative MRI study that examined 11 normal elderly (NL) volunteers and 6 Mild Cognitive Impairment (MCI) patients. After 4 years, all 6 MCI patients declined to AD and 2 of the NL subjects declined to MCI. At baseline and longitudinally, the MCI patients showed reduced delayed memory, increased IsoP levels, and reduced medial temporal lobe gray matter concentrations as compared to NL. A group comprised of all decliners to AD or to MCI (n = 8) was distinguished at baseline from the stable NL controls (n = 9) by IsoP with 100% accuracy.Moreover, both at baseline and longitudinally, the IsoP measures significantly improved the diagnostic and predictive outcomes of conventional memory testing and quantitative MRI measurements. These data indicate that IsoP is potentially useful for both the early detection of AD-related pathology and for monitoring the course of AD.

[1]  B. Reisberg,et al.  The Global Deterioration Scale for assessment of primary degenerative dementia. , 1982, The American journal of psychiatry.

[2]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[3]  M. Torrens.  Co-Planar Stereotaxic Atlas of the Human Brain—3-Dimensional Proportional System: An Approach to Cerebral Imaging, J. Talairach, P. Tournoux. Georg Thieme Verlag, New York (1988), 122 pp., 130 figs. DM 268 , 1990 .

[4]  Karl J. Friston,et al.  Comparing Functional (PET) Images: The Assessment of Significant Change , 1991, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[5]  Karl J. Friston,et al.  Statistical parametric maps in functional imaging: A general linear approach , 1994 .

[6]  Karl J. Friston,et al.  Spatial registration and normalization of images , 1995 .

[7]  R. Koeppe,et al.  A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  J. Trojanowski,et al.  Cerebrospinal fluid tau levels in neurodegenerative diseases with distinct tau-related pathology. , 1997, Biochemical and biophysical research communications.

[9]  J. Morrison,et al.  Life and death of neurons in the aging brain. , 1997, Science.

[10]  P. Diggle,et al.  Analysis of Longitudinal Data. , 1997 .

[11]  T. Montine,et al.  Increased CSF F2-isoprostane concentration in probable AD , 1999, Neurology.

[12]  S H Ferris,et al.  Neuropsychological Prediction of Decline to Dementia in Nondemented Elderly , 1999, Journal of geriatric psychiatry and neurology.

[13]  K. Blennow,et al.  Cerebrospinal fluid tau and Aβ42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment , 1999, Neuroscience Letters.

[14]  Karl J. Friston,et al.  Voxel-Based Morphometry—The Methods , 2000, NeuroImage.

[15]  J. Trojanowski,et al.  Increased 8,12‐iso‐iPF2α‐VI in Alzheimer's disease: Correlation of a noninvasive index of lipid peroxidation with disease severity , 2000, Annals of neurology.

[16]  M. Beal.  Energetics in the pathogenesis of neurodegenerative diseases , 2000, Trends in Neurosciences.

[17]  Nobuyuki Okamura,et al.  CSF Phosphorylated Tau Protein and Mild Cognitive Impairment: A Prospective Study , 2000, Experimental Neurology.

[18]  Y. Matsuoka,et al.  Fibrillar beta-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer's disease. , 2001, Neuroscience.

[19]  S. Rapoport,et al.  Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231 , 2001, Annals of neurology.

[20]  G. FitzGerald,et al.  The isoprostanes in biology and medicine , 2001, Trends in Endocrinology & Metabolism.

[21]  J. L. François,et al.  Fibrillar β-amyloid evokes oxidative damage in a transgenic mouse model of Alzheimer’s disease , 2001, Neuroscience.

[22]  A. Convit,et al.  Hippocampal formation glucose metabolism and volume losses in MCI and AD , 2001, Neurobiology of Aging.

[23]  Virginia M. Y. Lee,et al.  Increased Lipid Peroxidation Precedes Amyloid Plaque Formation in an Animal Model of Alzheimer Amyloidosis , 2001, The Journal of Neuroscience.

[24]  T. Montine,et al.  Cerebrospinal Fluid Aβ42, Tau, and F2-Isoprostane Concentrations in Patients With Alzheimer Disease, Other Dementias, and in Age-Matched Controls , 2001 .

[25]  T. Montine,et al.  Cerebrospinal fluid abeta42, tau, and f2-isoprostane concentrations in patients with Alzheimer disease, other dementias, and in age-matched controls. , 2001, Archives of pathology & laboratory medicine.

[26]  A. Nunomura,et al.  Oxidative Damage Is the Earliest Event in Alzheimer Disease , 2001, Journal of neuropathology and experimental neurology.

[27]  A. Convit,et al.  Longitudinal cerebrospinal fluid tau load increases in mild cognitive impairment , 2002, Neuroscience Letters.

[28]  Katharina Buerger,et al.  Differential diagnosis of Alzheimer disease with cerebrospinal fluid levels of tau protein phosphorylated at threonine 231. , 2002, Archives of neurology.

[29]  T. Montine,et al.  Lipid peroxidation in aging brain and Alzheimer's disease. , 2002, Free radical biology & medicine.

[30]  Karl J. Friston,et al.  Automatic Differentiation of Anatomical Patterns in the Human Brain: Validation with Studies of Degenerative Dementias , 2002, NeuroImage.

[31]  A Drzezga,et al.  Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment. , 2002, Archives of neurology.

[32]  Karl J. Friston,et al.  A Voxel-Based Morphometric Study of Ageing in 465 Normal Adult Human Brains , 2001, NeuroImage.

[33]  J. Trojanowski,et al.  Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. , 2002, Archives of neurology.

[34]  R. de Caterina,et al.  Low-Density Lipoprotein Level Reduction by the 3-Hydroxy-3-Methylglutaryl Coenzyme-A Inhibitor Simvastatin Is Accompanied by a Related Reduction of F2-Isoprostane Formation in Hypercholesterolemic Subjects: No Further Effect of Vitamin E , 2002, Circulation.

[35]  H. Arai,et al.  CSF tau protein phosphorylated at threonine 231 correlates with cognitive decline in MCI subjects , 2002, Neurology.

[36]  H. Möller,et al.  Differentiation of geriatric major depression from Alzheimer's disease with CSF tau protein phosphorylated at threonine 231. , 2003, The American journal of psychiatry.

[37]  Henry Rusinek,et al.  Regional brain atrophy rate predicts future cognitive decline: 6-year longitudinal MR imaging study of normal aging. , 2003, Radiology.

[38]  J. Trojanowski,et al.  Enhanced brain levels of 8,12-iso-iPF2α-VI differentiate AD from frontotemporal dementia , 2003, Neurology.

[39]  J. Wiltfang,et al.  Follow-up investigations in cerebrospinal fluid of patients with dementia with Lewy bodies and Alzheimer’s disease , 2005, Journal of Neural Transmission.

[40]  H. Möller,et al.  Value of CSF beta-amyloid1-42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment. , 2004, Molecular psychiatry.

[41]  T. Montine,et al.  Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. , 2004, Journal of Alzheimer's disease : JAD.

[42]  H. Möller,et al.  Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairment , 2004, Molecular Psychiatry.

[43]  K. Blennow.  CSF biomarkers for mild cognitive impairment , 2004, Journal of internal medicine.

[44]  D. Praticò,et al.  Increase in peripheral oxidative stress during hypercholesterolemia is not reflected in the central nervous system: evidence from two mouse models , 2005, Neurochemistry International.

[45]  Karl J. Friston,et al.  Mixed-effects and fMRI studies , 2005, NeuroImage.

[46]  Hilkka Soininen,et al.  CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment , 2005, Neurology.

[47]  A. Convit,et al.  The role of quantitative structural imaging in the early diagnosis of Alzheimer's disease. , 2005, Neuroimaging clinics of North America.

[48]  J. Morrow,et al.  Lipid peroxidation is an early event in the brain in amnestic mild cognitive impairment , 2005, Annals of neurology.

[49]  S. Santi,et al.  Cerebrospinal fluid biomarkers for mild cognitive impairment , 2006 .

[50]  K. Blennow,et al.  Dissociation between CSF total tau and tau protein phosphorylated at threonine 231 in Creutzfeldt–Jakob disease , 2006, Neurobiology of Aging.

[51]  A. Hofman,et al.  Use of hippocampal and amygdalar volumes on magnetic resonance imaging to predict dementia in cognitively intact elderly people. , 2006, Archives of general psychiatry.

[52]  J. Morrow,et al.  Increased levels of F2-isoprostanes following aneurysmal subarachnoid hemorrhage in humans. , 2006, Free radical biology & medicine.

[53]  M. Leon,et al.  Biomarkers for the early diagnosis of Alzheimer's disease , 2006, The Lancet Neurology.

[54]  B. Reisberg,et al.  Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment , 2006, Neurobiology of Aging.

[55]  K. Blennow,et al.  Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study , 2006, The Lancet Neurology.